About this Journal Submit a Manuscript Table of Contents
Experimental Diabetes Research
Volume 2012 (2012), Article ID 745189, 5 pages
http://dx.doi.org/10.1155/2012/745189
Clinical Study

Serum CA19-9 Level Associated with Metabolic Control and Pancreatic Beta Cell Function in Diabetic Patients

1School of Medicine, Shanghai Jiao Tong University, Shanghai 200233, China
2Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Diabetes Institute, Shanghai Clinical Center of Diabetes, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai 200233, China
3Department of medicine, Soochow University, Soochow 215006, China

Received 10 January 2012; Revised 15 March 2012; Accepted 15 April 2012

Academic Editor: Chien-Jen Chen

Copyright © 2012 Haoyong Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

CA19-9 is a tumor-associated antigen. It is also a marker of pancreatic tissue damage that might be caused by diabetes. Long-term poor glycemic control may lead to pancreatic beta cell dysfunction which is reflected by elevated serum CA19-9 level. Intracellular cholesterol accumulation leads to islet dysfunction and impaired insulin secretion which provide a new lipotoxic model. This study firstly found total cholesterol was one of the independent contributors to CA19-9. Elevated serum CA19-9 level in diabetic patients may indicate further investigations of glycemic control, pancreatic beta cell function, and total cholesterol level.